Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
24.74 USD -0.84% Intraday chart for BridgeBio Pharma, Inc. -7.79% -38.72%
Apr. 07 BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement CI
Mar. 20 JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating MT

Business Summary

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Number of employees: 553

Sales per Business

USD in Million2022Weight2023Weight Delta
Transformative Medicines
100.0 %
78 100.0 % 9 100.0 % -88.02%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
78 100.0 % 9 100.0 % -88.02%

Managers

Managers TitleAgeSince
Neil Kumar FOU
 Founder 45 14-12-31
Charles Homcy FOU
 Founder 75 14-12-31
Francis McCormick FOU
 Founder 73 14-12-31
Brian Stephenson DFI
 Director of Finance/CFO 43 18-09-30
Jonathan Fox PSD
 President 67 -
Uma Sinha CTO
 Chief Tech/Sci/R&D Officer 67 16-03-31
Christine Siu COO
 Chief Operating Officer 47 19-12-31
Richard Scheller CTO
 Chief Tech/Sci/R&D Officer 70 -
Vikram Bali IRC
 Investor Relations Contact - -
Adora Ndu LAW
 General Counsel 43 21-12-31

Members of the board

Members of the board TitleAgeSince
James Momtazee BRD
 Director/Board Member 52 16-02-29
Francis McCormick FOU
 Founder 73 14-12-31
Fred Hassan BRD
 Director/Board Member 78 21-08-16
Charles Homcy FOU
 Founder 75 14-12-31
Randal Scott BRD
 Director/Board Member 66 20-06-22
Richard Scheller CTO
 Chief Tech/Sci/R&D Officer 70 -
Douglas Dachille BRD
 Director/Board Member 59 21-08-16
Ali Satvat BRD
 Director/Board Member 46 16-02-29
Andrew Lo FOU
 Founder 63 14-12-31
Neil Kumar FOU
 Founder 45 14-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 189,895,402 141,030,466 ( 74.27 %) 6,191,761 ( 3.261 %) 74.27 %

Shareholders

NameEquities%Valuation
Kohlberg Kravis Roberts & Co. LP
16.84 %
31,060,971 16.84 % 960 M $
Viking Global Investors LP
13.62 %
25,120,991 13.62 % 777 M $
Vanguard Fiduciary Trust Co.
6.940 %
12,800,294 6.940 % 396 M $
BlackRock Advisors LLC
5.069 %
9,349,496 5.069 % 289 M $
Neil Kumar
3.728 %
6,875,932 3.728 % 213 M $
Aisling Capital Management LP
3.290 %
6,068,125 3.290 % 188 M $
Laurion Capital Management LP
2.842 %
5,241,833 2.842 % 162 M $
STATE STREET CORPORATION
2.758 %
5,086,899 2.758 % 157 M $
Cormorant Asset Management LP
1.813 %
3,344,179 1.813 % 103 M $
Goldman Sachs Asset Management LP
1.771 %
3,266,635 1.771 % 101 M $

Holdings

NameEquities%Valuation
LIANBIO
4.75%
 5,002,792 4.75% 1,615,902 $

Company contact information

BridgeBio Pharma, Inc.

3160 Porter Drive Suite 250

94304, Palo Alto

+650 391 9740

http://www.bridgebio.com
address BridgeBio Pharma, Inc.(BBIO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for BridgeBio Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
24.74 USD
Average target price
50.75 USD
Spread / Average Target
+105.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BRIDGEBIO PHARMA, INC. Stock BridgeBio Pharma, Inc.
-38.72% 4.6B
CSL LIMITED Stock CSL Limited
-5.99% 84.46B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.85B
BIOGEN INC. Stock Biogen Inc.
-24.88% 27.69B
UCB Stock UCB
+53.61% 24.28B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-8.08% 17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-33.74% 13.67B
INCYTE CORPORATION Stock Incyte Corporation
-16.63% 11.86B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.19% 11.79B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-2.25% 8.07B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. Company BridgeBio Pharma, Inc.